Your Messages Inbox
Your Article Summary
See Latest ArticlesSaxagliptin: DPP-4 inhibitor approved for the treatment of type 2 diabetes mellitus
Formulary , 09/17/09
Saxagliptin is an inhibitor of the dipeptidyl peptidase–4 enzyme. By inhibiting DPP–4, saxagliptin slows the inactivation of the incretin hormones, which increases their concentrations in the bloodstream and reduces both fasting and postprandial glucose concentrations in a glucose–dependent manner. Saxagliptin was approved on July, 2009, for use as monotherapy or as part of combination therapy as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Related Articles
Prevention of Type 2 Diabetes: Risk Status, Clinic, and Community
Journal of General Internal Medicine, 11/09/09
Relevance Score: 96%
Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 10/19/09
Relevance Score: 95%
Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study
Clinical Endocrinology, 10/16/09
Relevance Score: 94%
Periodontal Disease – The Overlooked Diabetes Complication
Nephrology Nursing Journal, 10/07/09
Relevance Score: 94%
Testing for monogenic diabetes among children and adolescents with antibody-negative clinically defined Type 1 diabetes
Diabetic Medicine, 10/05/09
Relevance Score: 94%
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
Article Search
Sponsor